tremfya 100 mg/ml soluţie injectabilă în seringă preumplută
janssen-cilag international nv - guselkumabum - soluţie injectabilă în seringă preumplută - 100 mg/ml
tremfya 100 mg/ml soluţie injectabilă în stilou injector (pen) preumplut
janssen-cilag international nv - guselkumabum - soluţie injectabilă în stilou injector (pen) preumplut - 100 mg/ml
tremfya 100 mg
janssen biologics b.v. - olanda - guselkumabum - sol. inj. - 100mg - imunosupresoare inhibitori de interleukina
tremfya
janssen-cilag international nv - guselkumab - psoriazis - imunosupresoare - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.
dupixent 200 mg
sanofi winthrop industrie - franta - dupilumabum - sol. inj. in seringa preumpluta - 175mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic
dupixent 200 mg
sanofi-aventis deutschland gmbh - franta - dupilumabum - sol. inj. in stilou injector (pen) preumplut - 175mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic
dupixent 300 mg
sanofi winthrop industrie - franta - dupilumabum - sol. inj. in seringa preumpluta - 150mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic
dupixent 300 mg
sanofi winthrop industrie - franta - dupilumabum - sol. inj. in stilou injector (pen) preumplut - 150mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic
spevigo
boehringer ingelheim international gmbh - spesolimab - psoriazis - imunosupresoare - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.